Product Description
Thrombin Inhibitor (Sourced from: https://pubs.acs.org/doi/abs/10.1021/op500134e)
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01150812 |
D2890C00001 | P1 |
Terminated |
Healthy Volunteers |
2010-08-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|